Prana Provides Update on PBT2 Alzheimer's Disease Extension Trial

Prana Biotechnology (NASDAQ:PRAN,ASX:PBT), which develops treatments for neurodegenerative disease, today provided an update of its IMAGINE Alzheimer’s Disease (AD) Extension trial.
As quoted in the market news:

On December 9, 2013 Prana announced that the treatment phase of the IMAGINE trial had completed with 95% of enrolled patients completing treatment (40 of a possible 42). Prana now confirms that a total of 33 patients chose to go into the Extension trial, representing 83% of the 40 patients who completed 12 months of treatment in the IMAGINE trial.

Read the full press release by Prana Biotechnology (NASDAQ:PRAN,ASX:PBT)